Benazepril – the step towards nephroprotection Review article
Article Sidebar
Published:
Dec 31, 2009
Keywords:
benazepril, amlodypine, chronic glomerulonephritis, proteinuria, renal function
Main Article Content
Abstract
Clinical practice guidelines recommend blockers of the renin-angiotensin system alone or in combination with other agents to reduce blood pressure and albuminuria in patients with type 2 diabetes. In the AIPRI study after 3-yr follow-up, benazepril provides renoprotection by a significant proteinuria reduction and risk reduction in the treatment group for doubling baseline serum creatinine concentration or the need for dialysis. In ACCOMPLISH and in GUARD trials drug combinations of benazepril and amlodypine proved the efficacy for patients with cardiovascular and kidney disease progression. Benazepril alone or in combination with CCB becomes the cornerstone strategy in the management of patients with chronic nephropaties with proteinuria and with chronic renal failure.
Article Details
How to Cite
Małecki , R. (2009). Benazepril – the step towards nephroprotection. Medycyna Faktow (J EBM), 2(4(5), 30-36. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2629
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Król E., Rutkowski B., Czarniak P. et al.: Early detection of chronic kidney disease: results of the PolNef study. Am. J. Nephrol. 2008; 29: 264-73.
2. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
3. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: P3-13.
4. Anderson S., Rennke H.G., Brenner B.W.: Therapeutic advantage of converting enzym inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
5. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
6. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
7. Balfour J.A., Goa K.L.: Benazepril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539.
8. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
9. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
10. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
11. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. New Engl. J. Med. 2006; 354: 131-140.
12. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
13. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
14. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
15. Jamerson K., Weber M.A., Bakris G.L. (for the ACCOMPLISH Trial Investigators): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
16. Bakris G.L., Toto R.D., McCullough P.A. et al. (on behalf of the GUARD Study Investigators): Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73, 1303-1309.
17. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
2. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
3. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: P3-13.
4. Anderson S., Rennke H.G., Brenner B.W.: Therapeutic advantage of converting enzym inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
5. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
6. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
7. Balfour J.A., Goa K.L.: Benazepril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539.
8. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
9. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
10. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
11. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. New Engl. J. Med. 2006; 354: 131-140.
12. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
13. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
14. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
15. Jamerson K., Weber M.A., Bakris G.L. (for the ACCOMPLISH Trial Investigators): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
16. Bakris G.L., Toto R.D., McCullough P.A. et al. (on behalf of the GUARD Study Investigators): Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73, 1303-1309.
17. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.